Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating reaffirmed by Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $3.00 price objective on the stock. Needham & Company LLC's price objective would suggest a potential upside of 164.32% from the company's current price.
A number of other equities analysts have also recently issued reports on LUCD. Wall Street Zen cut Lucid Diagnostics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. BTIG Research set a $2.00 target price on Lucid Diagnostics in a research note on Tuesday, March 25th. Ascendiant Capital Markets lifted their target price on Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a research note on Friday, June 6th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $2.00 target price on shares of Lucid Diagnostics in a research note on Thursday, May 15th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $3.55.
Get Our Latest Analysis on LUCD
Lucid Diagnostics Stock Performance
Shares of LUCD traded down $0.01 during trading hours on Wednesday, hitting $1.14. 452,336 shares of the company were exchanged, compared to its average volume of 705,624. The firm's 50 day moving average is $1.24 and its 200-day moving average is $1.23. Lucid Diagnostics has a 52 week low of $0.72 and a 52 week high of $1.80. The company has a market cap of $122.80 million, a PE ratio of -0.85 and a beta of 1.23.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Berkshire Asset Management LLC PA acquired a new stake in Lucid Diagnostics in the first quarter valued at $30,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Lucid Diagnostics in the first quarter valued at $37,000. Cubist Systematic Strategies LLC acquired a new stake in Lucid Diagnostics in the first quarter valued at $39,000. LPL Financial LLC increased its holdings in Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock valued at $44,000 after purchasing an additional 12,035 shares during the period. Finally, Parallel Advisors LLC acquired a new stake in Lucid Diagnostics in the second quarter valued at $46,000. 74.01% of the stock is currently owned by institutional investors.
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Recommended Stories
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
